Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2386]

$SABCS 2012: Hypofractionated radiotherapy was safe, effective for early breast cancer treatment at 10-year follow-up$

SABCS 2012: Hypofractionated radiotherapy was safe, effective for early breast cancer treatment at 10-year follow...

SABCS 2012: HDAC inhibitors sensitised triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

SABCS 2012: HDAC inhibitors sensitised triple-negative breast cancer cells to PARP inhibition and cisplatin...

SABCS 2012: Diverse genetic alterations found in triple-negative breast cancers after neoadjuvant chemotherapy

SABCS 2012: Diverse genetic alterations found in triple-negative breast cancers after neoadjuvant chemotherapy

SABCS 2012: Young women with breast cancer were more likely than older women to respond to neoadjuvant chemotherapy

SABCS 2012: Young women with breast cancer were more likely than older women to respond to neoadjuvant chemotherapy

SABCS 2012: Extending duration of adjuvant tamoxifen treatment to 10 years reduced risk for late breast cancer recurrence, improved survival

SABCS 2012: Extending duration of adjuvant tamoxifen treatment to 10 years reduced risk for late breast cancer...

SABCS 2012: Sentinel lymph node surgery after chemotherapy demonstrated accuracy in nodal staging for certain patients with breast cancer

SABCS 2012: Sentinel lymph node surgery after chemotherapy demonstrated accuracy in nodal staging for certain...

SABCS 2012: Combination of investigational agent and letrozole demonstrated clinical benefit in advanced ER-positive breast cancer

SABCS 2012: Combination of investigational agent and letrozole demonstrated clinical benefit in advanced ER...

Crizotinib launched in UK for patients with previously treated ALK-positive advanced NSCLC

Crizotinib launched in UK for patients with previously treated ALK-positive advanced NSCLC

Newly discovered effects of vitamin D on cancer

Newly discovered effects of vitamin D on cancer

Ponatinib acts against the most resistant types of chronic myeloid leukaemia

Ponatinib acts against the most resistant types of chronic myeloid leukaemia

More from ecancer